<DOC>
	<DOCNO>NCT02206776</DOCNO>
	<brief_summary>Obsessive-compulsive disorder ( OCD ) common illness cause significant distress impairment . Currently , serotonin reuptake inhibitor ( SRIs ) medication FDA-approved treat OCD . Unfortunately , SRIs take long time work ( 2-3 month ) , even usually partially reduce OCD symptom . The present study , test intranasal ketamine feasible use reduce OCD symptom significantly comparison medication call midazolam . Therefore , may may receive ketamine part study . Results study allow doctor researcher well understand others OCD may respond class medication .</brief_summary>
	<brief_title>Randomized Controlled Trial Intranasal Ketamine vs. Intranasal Midazolam Individuals With OCD</brief_title>
	<detailed_description />
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Age 1855 Physically healthy currently pregnant Primary diagnosis OCD Sufficient severity symptom For patient medication , medication dose must stable least 6 week prior enrollment . Must discuss Dr. current medication dos . Able provide consent First degree relative schizophrenia Psychiatric condition would make participation unsafe determine study doctor Female patient either pregnant nursing Planning start EX/RP period study complete adequate dose EX/RP ( define 8 session within 2 month ) within 8 week prior enrollment . Nasal obstruction history nasal surgery Currently psychotropic medication medication likely interact glutamate system Medical condition make participation unsafe Allergy intolerance ketamine midazolam</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>OCD</keyword>
</DOC>